Background--The evidence supporting the use of b-blockers in patients with acute coronary syndrome after successful percutaneous coronary intervention has been inconsistent and scarce.
b
-Blockers, as one of secondary prevention medications, can diminish myocardial oxygen demand by reducing heart rate, blood pressure, and myocardial contractility, thereby being widely used to relieve ischemic symptoms in patients with acute coronary syndrome (ACS). 1 The updated American
College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend the use of b-blockers for the management of ST-segment elevation myocardial infarction (STEMI) 2 and non-ST-segment elevation myocardial infarction (NSTEMI). 3 However, evidence supporting the clinical benefit of b-blockers is largely based on studies in patients with acute MI for STEMI, and was extrapolated to patients with unstable angina pectoris (UAP) and NSTEMI. 4 In the percutaneous coronary intervention (PCI) era, patients with ACS, a spectrum of clinical presentations ranging from UAP to NSTEMI and STEMI, mostly constituted those undergoing PCI. 5 However, few studies are available to systematically describe the contemporary pattern of b-blocker use and determine its impact on clinical outcomes in ACS patients after PCI. As Shachamet et al 6 pointed out, many physicians remain unconvinced of either a short-or long-term benefit of b-blocker use following PCI. Moreover, much less attention has been paid to specifying which subgroup of patients with ACS benefits the most from b-blocker therapy. Thus, we sought to evaluate the impact of b-blocker therapy on clinical outcomes in patients with ACS after PCI and specified subgroups in a "real-world" clinical setting.
Methods Study Population
All patients diagnosed with coronary heart disease at Tongji Hospital in Wuhan, China, were consecutively recruited in the Clinical Outcomes of Coronary Heart Diseases in Tongji Hospital registry from March 1, 2009 . Demographics, clinical profiles, and concomitant medications were collected with standardized case report forms by professional investigators in the department of cardiology, and all participants were prospectively contacted at 1, 6, and 12 months by cardiology nurses and research coordinators through patient interview, chart review, and serial telephone contacts. Written informed consent was obtained from each patient at admission. Between March 1, 2009 , and December 30, 2014 , all patients in the database were searched. For inclusion, patients were required to meet the following criteria: (1) age older than 18 years; (2) have an ascertained diagnosis of ACS at admission, and (3) undergoing PCI. In addition, the following patients were excluded from this analysis: (1) patients discharging unstable, (2) patients with the absence of b-blocker information at discharge, or (3) contraindication to b-blocker therapy such as significant bradycardia (heart rate <50 beat per min) or hypotension (systolic blood pressure <90 mm Hg). 
Definitions and Clinical End Points
For the purpose of calculating the proportion of b-blocker dose administered (daily dosage of b-blockers/target dose), the target dose was in line with b-blocker doses used in large randomized trials, defined as follows: documentation of angina pectoris. 13 Successful PCI was identified as a patent vessel at the treatment site with anterograde thrombolysis in myocardial infarction flow 3 and angiographic residual stenosis <50%. In the present study, we evaluated two study end points: (1) the primary outcome was all-cause mortality, which was regarded as cardiac origin unless obvious noncardiac cause could be identified; and (2) the secondary outcome was a composite end point of all-cause death, nonfatal MI, heart failure readmission, and cardiogenic hospitalization. Of these, MI referred to symptoms with new electrocardiographic changes (pathologic Q waves, persistent ST-segment elevation, or ST-segment depression) as well as cardiac markers at least one value above the 99th percentile of the upper reference limit. 14 The identification of heart failure readmission was consistent with the guidelines of the European Society of Cardiology. 15 In addition, cardiogenic hospitalization was considered as a hospitalization for cardiovascular cause, including UAP, transient ischemic attack, or revascularization procedure. The occurrence of clinical outcomes was systematically adjudicated by two independent physicians.
Statistical Analysis
Characteristics of study participants were expressed as meanAESD or percentage. We divided patients into two groups with regard to whether b-blocker therapy was received at discharge. 
Results

Study Cohort
Between March 1, 2009, and December 30, 2014, there were 5063 patients recruited in the database, and only 3453 patients underwent the PCI procedure. Of these, 23 patients were discharged unstably, 183 were not diagnosed with ACS at admission, 43 had a contraindication to b-blocker use, and 24 could not provide complete information about the administration of b-blockers at discharge, and were excluded from the analysis. Finally, 3180 patients were included in the evaluation cohort. The details are shown in Figure 1 .
b-Blocker Management at Discharge and Baseline Characteristics
In the overall evaluation cohort, 2423 patients (76.2%) were discharged on b-blockers, while 757 patients (23.8%) were not. Compared with b-blocker users, patients who were not administrated b-blockers were older (60.79AE10.39 versus Table 1 summarizes the baseline characteristics and other medication management according to the use of b-blockers at discharge. The differences in the baseline characteristics in the 3 subgroups are also shown in Tables 2 through 4. In the propensity score-matched model, there was no significant difference in the baseline characteristics between the b-blocker group and the no b-blocker group.
Clinical Outcomes
At 1 year after index admission, completed follow-up information was obtained in 3153 patients (99.2%). A total of 33 patients died of all-cause diseases, 14 patients occurred nonfatal MI, 34 patients had heart failure, and 214 patients were readmitted for cardiogenic reasons during follow-up. (Table 5 ). In the propensity score-matched cohort, the b-blocker group still had decreased all-cause mortality (HR, 0.27; 95% CI, 0.08-0.97 [P=0.045]) (Table 6 ). A lower rate of secondary end point was also observed in the b-blocker users (unadjusted HR, 0.76; 95% CI, 0.59-0.98 [P=0.035], although the statistical difference disappeared after adjustment (adjusted HR, 0.87; 95% CI, 0.66-1.16 [P=0.355]). In addition, the associations of b-blocker use with the rate of nonfatal MI, heart failure readmission, and cardiogenic hospitalization were computed, respectively. The results are illustrated in Table 5 , and Figure 2 describes the association between the use of b-blockers and clinical end points.
Subgroup Analyses
At baseline, 728 patients (22.9%) had STEMI, 576 patients (18.1%) had NSTEMI, and 1876 patients (59.0%) had UAP. We evaluated the relative b-blocker treatment effects in the subsets of patients with ACS. Notably, a greater benefit of bblocker use was found in patients with NSTEMI whose incidence of all-cause death was significantly lower in the bblocker group (0.2% versus 6.4%; unadjusted HR, 0.04; 95% CI, 0.00-0.27 [P=0.001]), and the relationship remained even after performing multivariable Cox proportional hazard regression analysis (adjusted HR, 0.00; 95% CI, 0.00-0.14 [P=0.005]). In addition, b-blocker use was associated with a lower risk of the secondary end point (7 Figure 2 ). The associations of b-blocker therapy with the clinical outcomes across the 3 subgroups were consistent in the propensity score-matched cohorts ( Table 6 ).
Doses of b-Blockers
Among the patients discharged on b-blockers, receiving <50% of target dose was reported in 2012 patients (83.0%), while 411 patients (17%) were prescribed ≥50% of target dose and the administration of metoprolol accounted for the majority (85.4%). The baseline characteristics according to the treatment of b-blocker use are exhibited in Table 1 (Figure 3) , and no differences were observed in the incidence of secondary end point between the three different b-blocker dose groups. Similar results were also obtained in patients with NSTEMI ( Figure 3 ).
Discussion
In this observational study, we investigated the association of b-blocker use with the clinical outcomes in patients with ACS undergoing PCI. We found that nearly 77% of eligible patients with ACS undergoing PCI were treated with b-blockers at discharge, and those not prescribed b-blockers were more likely to be older and have a history of arrhythmia. Importantly, b-blocker therapy at discharge, especially a relatively low b-blocker dosage, were independently associated with improved survival, and the efficacy was more significant in patients with NSTEMI. b-Blocker therapy also showed a trend in improved clinical outcomes in the STEMI and UAP patients. ACS as a major cause of emergency medical care and hospitalization worldwide 16 has been well improved by the introduction of PCI. 17 Optimal secondary medication remains important after successful PCI. Predecessors have highlighted the importance of b-blocker therapy in patients with acute myocardial infarction. [18] [19] [20] [21] [22] [23] [24] However, there are a few studies reporting that b-blocker use is not associated with improved outcome. [25] [26] [27] One meta-analysis of randomized trials on the clinical outcomes of b-blocker use indicated no mortality benefit but reduced recurrent myocardial infarction and angina (short-term) at the expense of increased heart failure, cardiogenic shock, and drug discontinuation. 28 In this metaanalysis, data used in the reperfusion era were mainly recruited from the Clopidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) 29 and the Japanese b-blockers and Calcium Antagonists Myocardial Infarction (JCBAMI) trial. 30 In COMMIT, the association between metoprolol allocation and risk of clinical outcomes was only assessed in a mean period of 15 days among AMI patients. On the other hand, only postmyocardial infarction patients were enrolled in the JCBAMI trial, which could not reflect the benefit of early b-blocker therapy on improvement in prognosis. Yet, our study proved the benefit of early use of b-blockers on long-term survival among patients with ACS. Nevertheless, Chan et al 31 reported the mortality benefit of b-blockers in patients undergoing successful elective PCI; however, they did not discuss which type of patients with ACS benefited the most.
In the present study, our results showed that b-blocker use was better associated with decreased incidence of all-cause death in patients with NSTEMI. The published Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA 33 studies also revealed that early b-blocker therapy had a beneficial impact on hospital and 6-month mortality in patients with NSTEMI. In addition, Yang et al 24 demonstrated that b-blocker therapy at discharge was associated with improved survival in STEMI patients treated with primary PCI and recommended long-term b-blocker therapy in all patients with STEMI regardless of risk profile. In our analysis, the use of b-blockers was not statistically associated with a lower risk of all-cause death in STEMI patients, but the trend of improved survival was obvious. Additionally, the observational data from the Outcome of b-blocker Therapy After Myocardial Infarction (OBTAIN) study suggested that increased survival was not observed in patients treated with b-blocker doses approximating those used in previous randomized clinical trials compared with lower doses, 34 which was consistent with our conclusions that relatively low b-blocker dose actually decrease the rate of all-cause mortality. Even though several investigators have studied the benefits of b-blocker use among patients with myocardial infarction, our study stressed the impact of b-blocker therapy, especially relatively low b-blocker dose, on reducing all-cause mortality in patients after elective PCI, and provided the evidence to support the idea that the benefit of oral b-blocker therapy might be confined to patients with NSTEMI. 35 Evidence has suggested that the benefit of b-blockers for patients with NSTEMI may be due to the multivessel disease commonly presenting in them and its sympathetic hyperactivity. [36] [37] [38] [39] However, further exploration of the clinical usefulness of b-blocker therapy in patients with ACS warrants large-scale clinical trials such as a recently registered project (NCT02648243). Finally, we cannot claim generalizability to patients with STEMI/UAP for it was underpowered to detect the difference. HF indicates heart failure; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; UAP, unstable angina pectoris. *The hazard ratio (HR) and 95% CI could not be evaluated that no event occurred in the b-blocker group.
Study Limitations
There were several limitations that deserve consideration. First, the nonrandomized nature of this observational study could have resulted in selection bias. Although randomized controlled trials are considered the highest standard for evaluating treatment efficacy, observational studies can still provide unique and valuable insights into treatment effectiveness and generalizability in practice. Our findings imply that the efficacy demonstrated in randomized clinical trials can be translated into tangible clinical benefits in the real world. Second, a 1-year follow-up period may be too short for conclusive determination of the long-term efficacy of b-blockers in the setting of ACS. Third, the STEMI group and the UAP group were underpowered to discriminate the benefit of b-blocker use.
Conclusions
This large observational study has shown that the higher survival rate in patients following PCI is associated with the appropriate use of b-blockers at discharge and this benefit is consistent in the patients with NSTEMI. The adjusted hazard ratio (HR) and 95% CI could not be evaluated that no event occurred in the ≥50% of target dose group. MI indicates myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; UAP, unstable angina pectoris.
